Devices & Intervention · Note 09
FDA approves stroke prevention devices used during transcarotid artery revascularization
The FDA approved stroke prevention devices used during transcarotid artery revascularisation after Contego Medical's PERFORMANCE III study produced positive data.
Carotid artery disease raises stroke risk, and treating it means either open surgery or a catheter-based approach. Transcarotid artery revascularisation, or TCAR, combines a small neck incision with a stent and a flow-reversal system designed to keep debris from travelling to the brain during the procedure.
The FDA approvals cover devices used to protect the brain during TCAR. They follow the PERFORMANCE III IDE study, which was designed to evaluate safety and performance in a regulated clinical trial rather than a single-centre experience. Device approvals often hinge on fewer patients than drug approvals, so the quality of the registry follow-up matters.
For clinicians, the new approvals expand the toolkit for patients who are poor candidates for open surgery. For patients, the key question remains whether the protection system reduces stroke without adding procedural risk. The original coverage should be read for the specific devices and trial endpoints.
Keep in mind
- The approvals followed the PERFORMANCE III IDE study.
- Device choice depends on anatomy and surgical risk.
Source and reuse
This is an independent editorial summary written for Heartline. It is not a verbatim reproduction and does not reproduce paywalled text. Reporting, data and quotations belong to Cardiovascular Business. Read the original at the link provided.
Metadata basis: the publisher’s public RSS feed and the abstract it exposes. Where the full article could not be accessed, this note is explicitly metadata-based and limited to what the feed disclosed. It is not medical advice.
Read the original at Cardiovascular Business →